Attention deficit hyperactivity disorder and comorbid substance abuse

Clinical Aspects of Psychopharmacology in Childhood and Adolescence

Volumn , Issue , 2011, Pages 31-50

  Ivanov, Iliyan ^a,b,c   Pearson, Andrew ^a,b,c   Kaplan, Gabriel ^a,b,c   Newcorn, Jeffrey H ^a,b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Hoboken University Medical Center   (United States)

^c UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84924041756     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (68)

1. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2005 National Survey on Drug Use and Health: [National findings]. Rockville, MD: Author, 2006.
2. Mariani JJ, Levin FR. Treatment strategies for co-occurring ADHD and substance abuse disorders. [Am J Addict] 2007;16:45-54.
3. Shrier LA, Harris SK, Kurland M, Knight JR. Substance use problems and associated psychiatric symptoms among adolescents in primary care. [Pediatrics] 2003;111:e699.-e705.
4. Lynskey MT, Fergusson DM. Childhood conduct problems, attention deficit behaviors, and adolescent alcohol, tobacco, and illicit drug use. [J Abnorm Child Psychol] 1995;23:281-302.
5. Gordon SM, Tulak F, Troncale J. Prevalence and characteristics of adolescent patients with cooccurring ADHD and substance dependence. [J Addict Dis] 2004;23:31-40.
6. Dennis M, Godley SH, Diamond G, Tims FM, Babor T, Donaldson J, et al. The Cannabis Youth Treatment (CYT) Study: main findings from two randomized trials. [J Subst Abuse Treat] 2004;27(3):197-213.
7. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult psychiatric status of hyperactive boys grown up. [Am J Psychiatry] 1998;155: 493-8.
8. Elkins IJ, McGue M, Iacono WG. Prospective effects of attention-deficit/hyperactivity disorder, conduct disorder, and sex on adolescent substance use and abuse. [Arch.Gen.Psychiatr] 2007; 64:1145-52.
9. Pomerleau OF, Downey KK, Stelson FW, Pomerlau CS. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. [J Subst Abuse] 1995;7:373-8.
10. Upadhyaya HP. Do patients with ADHD have a harder time quitting cigarettes [J Am Acad Child] Adolesc Psychiatry 2006;45:891.
11. DeWit DJ, Adlaf EM, Offord DR, Ogborne AC. Age at first alcohol use: a risk factor for the development of alcohol disorders. [Am J Psychiatry] 2000;157(5):745-50.
12. Grant BF, Dawson DA. Age of onset of drug use and its association with DSM-IV drug abuse and dependence: results from the National Longitudinal Alcohol Epidemiologic Survey. [J Subst Abuse] 1998;10(2):163-73.
13. Hingson RW, Heeren T, Jamanka A, Howland J. Age of drinking onset and unintentional injury involvement after drinking. [JAMA] 2000;284(12):1527-33.
14. Rogers PD, Copley L. The nonmedical use of prescription drugs by adolescents. [Adolesc Med State Art Rev] 2009;20(1):1-8, vii.
15. Klein-Schwartz W, McGrath J. Poison centers’ experience with methylphenidate abuse in pre-teens and adolescents. [J Amer Acad Child Adolesc Psychiatry] 2003;42(3):288-94.
16. McCabe SE, Teter C J, Boyd C J. Medical use, illicit use, and diversion of abusable prescription drugs. [J Amer Coll Health] 2006;54(5):269-78.
17. Rabiner DL, Anastopoulos AD, Costello EJ, Hoyle RH, McCabe SE, Swartzwelder HS. The misuse and diversion of prescribed ADHD medications by college students. [J Atten Disord] 2009;13(2):144-53.
18. McCabe SE, Knight JR, Teter CJ, Wechsler H. Non-medical use of prescription stimulants among US college students: Prevalence and correlates from a national survey. [Addiction] 2005;100(1): 96-106.
19. McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use and diversion of prescription stimulant medication. [J Psychoactive Dr] 2006;38(1):43-56.
20. Teter C J, McCabe SE, LaGrange K, Cranford J, Boyd CJ. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. [Pharmacotherapy] 2006;26(10):1501-10.
21. Barrett SP, Darredeau C, Pihl RO. Patterns of simultaneous polysubstance use in drug using university students. [Hum Psychopharmacol] 2006;21(4):255-63.
22. Upadhyaya HP, Rose K, Wang W, O'Rourke K, Sullivan B, Deas D, Brady KT. Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults. [J Child Adolesc Psychopharmacol] 2005;15:799-809.
23. Wilens TE, Biederman J, Mick E, Faraone SV, Spencer T. Attention-deficit/hyperactivity disorder (ADHD) is associated with early onset substance use disorders. [J Nerv Ment Dis] 1997;185:475-82.
24. Schubiner H, Tzelepis A, Milberger S, Lockhart N, Kruger M, Kelley BJ, Schoener EP. Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. J [Clin Psychiatry] 2000;61:244-51.
25. Carroll KM, Rounsaville BJ. History and significance of childhood attention-deficit disorder in treatment-seeking cocaine abusers. [Compr Psychiatry] 1993;34:75-82.
26. Kollins SH. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. [J Clin Psychiatry] 2003;(64 Suppl):11: 14-8.
27. Kollins SH, MacDonald EK, Rush CR. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. [Pharmacol Biochem Behav] 2001;68:611-27.
28. Sax KW, Strakowski SM. Behavioral sensitization in humans. [J Addict Dis] 2001;20:55-65.
29. Vitiello B. Long-term effects of stimulant medications on the brain: possible relevance to the treatment of attention-deficit/hyperactivity disorder. [J Child Adolesc Psychopharmacol] 2001;11:25-34.
30. Martin CA, Guenthner G, Bingcang C, Rayens MK, Kelly TH. Measurement of the subjective effects of methylphenidate in 11- to 15-year-old children with attention-deficit/hyperactivity disorder. [J Child Adolesc Psychopharmacol] 2007;17(1):63-73.
31. Fredericks EM, Kollins SH. A pilot study of methylphenidate preference assessment in children diagnosed with attention deficit/hyperactivity disorder. [J Child Adolesc Psychopharmacol] 2005;15:729-41.
32. Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F, et al. Evaluating dopamine reward pathway in ADHD: clinical implications. [JAMA] 2009;302(10):1084-91.
33. Dierker LC, Vesel F, Sledjeski EM, Costello D, Perrine N. Testing the dual pathway hypothesis to substance use in adolescence and young adulthood. [Drug Alcohol Depend] 2007;87(1):83-93.
34. Williams J, Klinepeter K, Palmes G, Pulley A, Foy JM. Diagnosis and treatment of behavioral health disorders in pediatric practice. [Pediatrics] 2004;114:6016.
35. Bernal P. Hidden morbidity in pediatric primary care. [Pediatr Ann] 2003;32:413-8
36. Wise BK, Cuffe SP, Fischer T. Dual diagnosis and successful participation of adolescents in substance abuse treatment. [J Subst Abuse Treat] 2001;21(3):161-5.
37. White AM, Jordan JD, Schroeder KM, Acheson SK, Georgi BD, Sauls G, et al. Predictors of relapse during treatment and treatment completion among marijuana-dependent adolescents in an intensive outpatient substance abuse program. [Subst Abus] 2004;25(1):53-9.
38. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, text rev. Washington, DC: [APA], 2000.
39. Bukstein OG, Bernet W, Arnold V, Beitchman J, Shaw J, Benson RS, et al. Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with substance use disorders. [J Am Acad Child Adolesc Psychiatry] 2005;44:609-21.
40. Huss M, Lehmkuhl U. Methylphenidate and substance abuse: A review of pharmacology, animal, and clinical studies. [J Atten Disord] 2002;6(Suppl 1):S65-S71.
41. Lambert NM, Hartsough CS. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. [J Learning Disabil] 1998;31(6):533-44.
42. Schenk S, Partridge B. Sensitization and tolerance in psychostimulant self-administration. [Pharmacol Biochem Behav] 1997;57(3): 543-50.
43. Piazza PV, Deminiere JM, le Moal M, Simon H. Stress- and pharmacologically-induced behavioral sensitization increases vulnerability to acquisition of amphetamine self-administration. [Brain Res] 1990;514(1):22-6.
44. Mannuzza S, Klein RG, Moulton JL. Does stimulant treatment place children at risk for adult substance abuse? A controlled, prospective follow-up study. [J Child Adolesc Psychopharmacol] 2003;13(3):273-82.
45. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. [Pediatrics] 2003;111(1):179-85.
46. Faraone SV, Biederman J, Wilens TE, Adamson J. A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults. [Psychol Med] 2007;37:1-10.
47. Biederman J, Wilens T, Mick E, Spencer T, Faraone SV. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. [Pediatrics] 1999;104(2): e20.
48. Mague SD, Andersen SL, Carlezon WA. Early developmental exposure to methylphenidate reduces cocaineinduced potentiation of brain stimulation reward in rats. [Biol Psychiatr] 2005;57(2):120-5.
49. Brandon CL, Marinelli M, White FJ. Adolescent exposure to methylphenidate alters the activity of rat midbrain dopamine neurons. [Biol Psychiatr] 2003;54(12):1338-44.
50. Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of alcohol dependence: a review of the evidence. [JAMA] 1999;281(14): 1318-25.
51. Cornelius JR, Bukstein OG, Birmaher B, Salloum IM, Lynch K, Pollock NK, et al. Fluoxetine in adolescents with major depression and an alcohol use disorder: an open-label trial. [Addict Behav] 2001;26(5):735-9.
52. Riggs PD, Leon SL, Mikulich SK, Pottle LC. An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder. [J Am Acad Child Adolesc Psychiatry] 1998;37(12):1271-8.
53. Riggs PD, Mikulich SK, Coffman LM, Crowley TJ. Fluoxetine in drug-dependent delinquents with major depression: an open trial.[J Child Adolesc Psychopharmacol] 1997;7(2):87-95.
54. Castaneda R, Levy R, Hardy M, Trujillo M. Long-acting stimulants for the treatment of attention-deficit disorder in cocaine-dependent adults. [Psychiatr Serv] 2000;51:169-71.
55. Schubiner H, Saules KK, Arfken CL, Johanson CE, Schuster CR, Lockhart N, et al. Double-blind, placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. [Exp Clin Psychopharmacol] 2002;10:286-94.
56. Levin FR, Evans SM, McDowell, DM, Kleber HD. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. [J Clin Psychiatry] 1998;59:300-5
57. Carpentier PJ, de Jong CA, Dijkstra BA, Verbrugge CA, Krabbe PF. A controlled trial of methylphenidate in adults with attention-deficit/hyperactivity disorder and substance use disorders. [Addiction] 2005;100:1868-74.
58. Melville N. OROS-Methylphenidate, placebo show equal efficacy for adolescents with ADHD and substance abuse disorders. [Medscape Today] 2009 Dec 9.
59. Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. [J Psychopharmacol] 2009;23(4):419-27.
60. Heil SH, Holmes HW, Bickel WK, Higgins ST, Badger GJ, Laws HF. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. [Dr Alcohol Dependence] 2002;67(2):149-56.
61. Lile JA, Stoops WW, Durell TM, Glaser PE, Rush CR. Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans. [Exper Clin Psychopharmacology] 2006;14(2):136-47.
62. Daviss WB, Bentivoglio P, Racusin R, Brown KM, Bostic JQ, Wiley L. Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. [J Am Acad Child Adolesc Psychiatry] 2001;40(3):307-34.
63. Wilens TE, Spencer TJ, Biederman J, Girard K, Doyle R, Prince J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. [Am J Psychiatry] 2001;158(2):282-8.
64. Swanson JM, Greenhill LL, Lopez FA, Sedillo A, Earl CQ, Jiang JG, Biederman J. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. [J Clin Psychiatry] 2006;67(1):137-47.
65. Wilens TE, Biederman J, Prince J, Spencer TJ, Faraone SV, Warburton R, et al. Six-week, doubleblind, placebocontrolled study of desipramine for adult attention deficit hyperactivity disorder. [Am J Psychiatry] 1996;153(9):1147-53.
66. Adler LA, Resnick S, Kunz M, Devinsky O. Open label trial of venlafaxine in adults with attention deficit disorder. [Psychopharmacol Bull] 1995;31(4):785-8.
67. Riggs PD, Mikulich-Gilbertson SK, Davies RD, Lohman M, Klein C, Stover SK. A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. [Arch Pediatr Adolesc Med] 2007;161(11): 1026-34.
68. Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. [J Amer Acad Child Adolesc Psychiatry] 2006;45(4):408-14.